2025
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy
Bhatt D, Sundaram R, López K, Lee T, Gueble S, Vasquez J. Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy. Current Protocols 2025, 5: e70097. PMID: 39995104, DOI: 10.1002/cpz1.70097.Peer-Reviewed Original ResearchConceptsImproved response to immune checkpoint blockadeGlioma modelResponse to immune checkpoint blockadeAlkylating agentsImmune checkpoint blockadeIncrease tumor immunogenicityMurine glioma modelMurine glioma cell lineResponse to alkylating agentsResistance to temozolomideDNA repair genotypesMMR deficiencyAntitumor immunityCheckpoint blockadeTumor immunogenicityMedian survivalImmunocompetent modelDismal prognosisMismatch repairMismatch repair deficiencyGlioma cell linesIntracranial tumorsAlkylating chemotherapySomatic lossSomatic acquisition
2024
Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment
Singh K, Abdou H, Panth N, Chiang V, Buono F, Schwartz N, Mahajan A. Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment. Otology & Neurotology 2024, 46: 196-200. PMID: 39792983, DOI: 10.1097/mao.0000000000004392.Peer-Reviewed Original ResearchConceptsTumor volume assessmentABC/2 methodVestibular schwannomaVolume assessmentPlanimetry methodTumor volumeTumor volume changesFollow-up scansOverestimate tumor volumePatients' quality of lifeTumor sizeRetrospective reviewIntracranial tumorsImprove clinical decision makingSubgroup analysisVolumetric assessmentTumorClinical decision makingQuality of lifePatients' qualityPatientsClinical settingPlanimetryImaging techniquesPositive correlationPerivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.
Choudhury A, Cady M, Lucas C, Najem H, Phillips J, Palikuqi B, Zakimi N, Joseph T, Birrueta J, Chen W, Oberheim Bush N, Hervey-Jumper S, Klein O, Toedebusch C, Horbinski C, Magill S, Bhaduri A, Perry A, Dickinson P, Heimberger A, Ashworth A, Crouch E, Raleigh D. Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy. Cancer Discovery 2024, 14: 1823-1837. PMID: 38742767, PMCID: PMC11452293, DOI: 10.1158/2159-8290.cd-23-1459.Peer-Reviewed Original ResearchConceptsResistance to radiotherapyMeningioma tumorigenesisSystemic therapyTreating meningiomasStem cellsGenetically engineered mouse modelsTumor-initiating capacityHigh-grade meningiomasReduced tumor growthPrimary intracranial tumorsMeningioma growthImproved survivalIntracranial tumorsRadiotherapyTherapeutic vulnerabilitiesTumor growthMeningiomasMouse modelSingle-cell transcriptomicsLineage tracingNotch3TumorigenesisCell proliferationReduced survivalCell types
2023
Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology
Qureshi H, Tabor J, Pickens K, Lei H, Vasandani S, Jalal M, Vetsa S, Elsamadicy A, Marianayagam N, Theriault B, Fulbright R, Qin R, Yan J, Jin L, O’Brien J, Morales-Valero S, Moliterno J. Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology. Journal Of Neuro-Oncology 2023, 164: 299-308. PMID: 37624530, PMCID: PMC10522517, DOI: 10.1007/s11060-023-04416-1.Peer-Reviewed Original ResearchBrain tumor patientsTumor patientsPostoperative outcomesFrailty indexSystematic reviewBrain tumorsPrimary intracranial tumorsMethodsSystematic literature reviewPrognostic valueVestibular schwannomaPostsurgical outcomesBenign tumorsIntracranial tumorsLesion etiologyTumor outcomeExclusion criteriaMalignant lesionsPRISMA guidelinesPatientsConclusionOur reviewTumor pathologyUnique etiologyTumor typesFrailtyNeurosurgical oncologyAssessment of the impact of frailty on adverse surgical outcomes in patients undergoing surgery for intracranial tumors using modified frailty index: A systematic review and meta-analysis
Aghajanian S, Shafiee A, Ahmadi A, Elsamadicy A. Assessment of the impact of frailty on adverse surgical outcomes in patients undergoing surgery for intracranial tumors using modified frailty index: A systematic review and meta-analysis. Journal Of Clinical Neuroscience 2023, 114: 120-128. PMID: 37390775, DOI: 10.1016/j.jocn.2023.06.013.Peer-Reviewed Original ResearchConceptsImpact of frailtyFrailty indexMFI scoreAdverse outcomesReoperation rateIntracranial tumorsNon-frail participantsAdverse surgical outcomesNeuro-oncological surgeryWeb of SciencePerioperative outcomesComplication rateIndependent predictorsSurgical outcomesWorse prognosisMean ageObservational studySurgical pathologyMixed-effects multilevel modelsPrimary analysisSystematic reviewNeurosurgical proceduresFrailtySurgical operationSurgeryPersonality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI)
Puthenpura V, Nadkarni S, DiLuna M, Hieftje K, Marks A. Personality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI). Cureus 2023, 15: e36408. PMID: 37090271, PMCID: PMC10115215, DOI: 10.7759/cureus.36408.Peer-Reviewed Original ResearchLow-grade gliomasIntracranial tumorsPersonality changesTreatment of LGGCentral nervous system tumorsMain presenting featuresBroad differential diagnosisNervous system tumorsPresenting featuresPediatric patientsCase reportSystem tumorsFavorable outcomeEndocrine conditionsMain symptomsDifferential diagnosisIntracranial neoplasmsBrain tumorsGrade gliomasEarly identificationSymptomsTumorsOlder childrenCommon typeNatural language processing tools
2021
STEM-27. A PERIVASCULAR STEM CELL UNDERLIES VERTEBRATE MENINGEAL TUMORIGENESIS
Choudhury A, Cady M, Lucas C, Palikuqi B, Klein O, Hervey-Jumper S, Phillips J, Dickinson P, Magill S, Bhaduri A, Crouch E, Raleigh D. STEM-27. A PERIVASCULAR STEM CELL UNDERLIES VERTEBRATE MENINGEAL TUMORIGENESIS. Neuro-Oncology 2021, 23: vi26-vi27. DOI: 10.1093/neuonc/noab196.101.Peer-Reviewed Original ResearchHuman meningiomasBackground MeningiomasStem cellsGenetically engineered mouse modelsCancer stem cell genesClonogenic growth in vitroRNA sequencingDecreased overall survivalStem cell approachesPrimary intracranial tumorsPerivascular stem cell nicheExpression of Notch3Stem cell genesCell typesCopy number variants identificationTumor growth in vivoNon-tumor cellsStem cell nicheGrowth in vivoGrowth in vitroOverall survivalPerivascular stem cellsIntracranial tumorsTumor cellsMeningiomasA molecularly integrated grade for meningioma
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi W. A molecularly integrated grade for meningioma. Neuro-Oncology 2021, 24: 796-808. PMID: 34508644, PMCID: PMC9071299, DOI: 10.1093/neuonc/noab213.Peer-Reviewed Original ResearchConceptsMeningioma patientsWHO gradeGrading systemCommon primary intracranial tumorWorld Health Organization gradeProgression-free survivalAdditional prognostic informationPrimary intracranial tumorsCox proportional hazardsGrading schemeTime-dependent areaSurgical resectionChromosomal copy-number dataClinical behaviorHistopathology featuresPrognostic informationPatient managementIntracranial tumorsDiscovery cohortClinical careIndependent cohortMitotic countPatientsProportional hazardsMeningiomasMultiple meningiomas arising within the same hemisphere associated with Li-Fraumeni syndrome
Hong CS, Erson-Omay EZ, Moliterno J. Multiple meningiomas arising within the same hemisphere associated with Li-Fraumeni syndrome. Surgical Neurology International 2021, 12: 99. PMID: 33880204, PMCID: PMC8053471, DOI: 10.25259/sni_125_2019.Peer-Reviewed Original ResearchLi-Fraumeni syndromeMultiple meningiomasWorld Health Organization grade ITime of presentationCommon intracranial tumorsWhole-exome sequencingGeneralized seizuresPatient populationMedical historyGrade IIntracranial tumorsMeningiomasSyndromeNovel presentationRight hemisphereHeterozygous deletionPatientsTumors
2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Nabors L, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian J, Clark S, Fabiano A, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler J, Mrugala M, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli V, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve D, Swinnen L, Weiss S, Wen P, Willmarth N, Bergman M, Darlow S. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1537-1570. PMID: 33152694, DOI: 10.6004/jnccn.2020.0052.Peer-Reviewed Original ResearchConceptsCentral nervous system cancerNervous system cancersCNS cancersSystem cancersNCCN Clinical Practice GuidelinesMetastatic brain diseaseClinical practice guidelinesNCCN guideline recommendationsCommon intracranial tumorsNCCN guidelinesBrain metastasesGuideline recommendationsGrade IIntracranial tumorsPractice guidelinesPilocytic astrocytomaBrain tumorsAppropriate managementBrain diseasesCancerRadiation therapistsTumorsInterdisciplinary teamGliomasStandard practiceRadiation Necrosis Following the Radiosurgical Treatment of Brain Metastases
Robert S, Chiang V. Radiation Necrosis Following the Radiosurgical Treatment of Brain Metastases. 2020, 393-405. DOI: 10.1007/978-3-030-42958-4_28.ChaptersMetastatic brain lesionsRadiation necrosisBrain lesionsStereotactic radiosurgeryRadiation-induced side effectsImmune system involvementEffective treatment modalityMetastatic intracranial tumorsBrain metastasesSystemic cancerTreatment modalitiesUnderlying pathophysiologySystem involvementDisease entityIntracranial tumorsRadiosurgical treatmentSide effectsTumor progressionBrain tissueNecrosisConcurrent useLesionsRadiosurgeryImaging modalitiesLife expectancyMolecular and clonal evolution in recurrent metastatic gliosarcoma
Anderson K, Tan A, Parkinson J, Back M, Kastelan M, Newey A, Brewer J, Wheeler H, Hudson A, Amin S, Johnson K, Barthel F, Verhaak R, Khasraw M. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Molecular Case Studies 2020, 6: a004671. PMID: 31896544, PMCID: PMC6996521, DOI: 10.1101/mcs.a004671.Peer-Reviewed Original ResearchConceptsFirst recurrenceExtracranial metastasesIntracranial tumorsFrontal lobeRight iliac boneLeft frontal lobeOrigin of metastasesFrontal recurrenceMetastatic gliosarcomaConcurrent radiotherapyFurther surgeryFurther recurrenceRecurrent tumorsMetastatic tumorsIliac boneMetastasisRecurrenceTumorsMesenchymal typeSurgeryClonal relationshipRadiotherapyGliosarcomaMolecular profilePelvic bones
2018
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine 2018, 24: 1459-1468. PMID: 30104766, PMCID: PMC6129206, DOI: 10.1038/s41591-018-0135-2.Peer-Reviewed Original ResearchConceptsT cell dysfunctionT cellsBone marrowCell dysfunctionT cell sequestrationTreatment-naïve subjectsT-cell lymphopeniaNaïve T cellsSetting of glioblastomaT cell surfaceCD4 countLymphoid organsImmune escapeCell lymphopeniaIntracranial tumorsCell sequestrationMurine modelIntracranial compartmentGlioblastomaMarrowDysfunctionTumorsCancerCellsCell surface
2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
Antonios J, Soto H, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 10220-10225. PMID: 28874539, PMCID: PMC5617282, DOI: 10.1073/pnas.1706689114.Peer-Reviewed Original ResearchConceptsPD-1Dendritic cellsMAb blockadeTumor lysate-pulsed DC vaccineHost antitumor immune responseTreated with dendritic cellsImmune responseDetection of immune responsesClinical management of patientsPET probeAntitumor immune responseTumor-infiltrating lymphocytesSyngeneic immunocompetent miceContrast enhancementSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakeNoninvasive imaging techniquesImmune inflammatory responseDC vaccinesImmunocompetent miceIntracranial tumorsImaging techniquesMalignant gliomas
2016
PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016, 105: 136-144. PMID: 27521616, PMCID: PMC5072177, DOI: 10.1016/j.biomaterials.2016.07.037.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryGlioblastoma multiformeChemotherapeutic drugsFirst-line treatmentExtracranial solid tumorTumor-bearing animalsSurvival of animalsBrain extracellular spaceLine treatmentTumor bedIntracranial tumorsOrthotopic modelTreatment resistanceSolid tumorsGBM treatmentTherapeutic efficacyNew treatmentsTumor tissueHealthy animalsGBM prognosisFree gemcitabineMR contrast agentsNucleoside analoguesDrugsGemcitabineSuccess and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions
Corso CD, Bindra RS. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars In Radiation Oncology 2016, 26: 281-298. PMID: 27619250, DOI: 10.1016/j.semradonc.2016.06.003.Peer-Reviewed Original ResearchConceptsCurrent standard treatmentGlioblastoma multiformeStandard treatmentTreatment of GBMDistant brain relapseAggressive intracranial tumorBrain relapseAggressive therapyModality therapySurgical resectionCombined modalityIntracranial tumorsModality approachOncology communityTherapyMultiformeTreatmentUnanswered questionsImmunotherapyResectionRelapseFailureTumorsDistribution of polymer nanoparticles by convection-enhanced delivery to brain tumors
Saucier-Sawyer JK, Seo YE, Gaudin A, Quijano E, Song E, Sawyer AJ, Deng Y, Huttner A, Saltzman WM. Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. Journal Of Controlled Release 2016, 232: 103-112. PMID: 27063424, PMCID: PMC4893898, DOI: 10.1016/j.jconrel.2016.04.006.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryBlood-brain barrierBrain-penetrating nanoparticlesIntracranial tumorsBrain tumorsGlioblastoma multiformeHealthy brainMain tumor massFatal brain tumorPresence of tumorBrain tumor treatmentLocal recurrenceInfusion sitePeritumoral tissuesTumor massCED infusionIndividual tumorsTumorsNecrotic regionsTumor treatmentLocal administrationHeterogeneous distribution patternAdministrationBrainCell targeting
2015
Craniopharyngioma arising in a Rathke's cleft cyst: case report.
Alomari AK, Kelley BJ, Damisah E, Marks A, Hui P, DiLuna M, Vortmeyer A. Craniopharyngioma arising in a Rathke's cleft cyst: case report. Journal Of Neurosurgery Pediatrics 2015, 15: 250-4. PMID: 25555112, DOI: 10.3171/2014.11.peds14370.Peer-Reviewed Original ResearchConceptsRathke's cleft cystCleft cystDecreased visual acuityFocal squamous metaplasiaHistological findingsSquamous metaplasiaVisual acuityCase reportRim enhancementSellar lesionsSerial MRIIntracranial tumorsKi-67Histological examinationBRAF mutationsYears durationSellar regionLesion typeLesionsResidual enhancementCraniopharyngiomaMolecular classificationEctodermal lesionsPatientsCysts
2013
Expression and Functional Heterogeneity of Chemokine Receptors CXCR4 and CXCR7 in Primary Patient-Derived Glioblastoma Cells
Liu C, Pham K, Luo D, Reynolds BA, Hothi P, Foltz G, Harrison JK. Expression and Functional Heterogeneity of Chemokine Receptors CXCR4 and CXCR7 in Primary Patient-Derived Glioblastoma Cells. PLOS ONE 2013, 8: e59750. PMID: 23555768, PMCID: PMC3605406, DOI: 10.1371/journal.pone.0059750.Peer-Reviewed Original ResearchConceptsFunction of CXCR4Chemokine receptor CXCR4CXCR4-CXCR7Receptor CXCR4Common primary brain tumorPrimary human GBM cellsPrimary brain tumorsPersonalized treatment approachesTube formationSurface expressionPatient-derived GBM cell linesNew therapeutic targetsCell linesHuman GBM cellsPatient-derived glioblastoma cellsGBM cell linesClinical benefitPoor prognosisSuccessful treatmentCell surface expressionCXCR7 axisCXCL12-CXCR4Intracranial tumorsGBM patientsBrain tumors
2012
Assessment of Autoantibodies to Meningioma in a Population-based Study
Wiemels JL, Bracci PM, Wrensch M, Schildkraut J, Bondy M, Pfefferle J, Zhou M, Sison J, Calvocoressi L, Claus EB. Assessment of Autoantibodies to Meningioma in a Population-based Study. American Journal Of Epidemiology 2012, 177: 75-83. PMID: 23221727, PMCID: PMC3590036, DOI: 10.1093/aje/kws221.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, NuclearAutoantibodiesBiomarkers, TumorCell Cycle ProteinsDNA-Binding ProteinsEczemaFemaleHumansHypersensitivityMaleMeningiomaMiddle AgedNuclear Matrix-Associated ProteinsPhosphopyruvate HydrataseReceptors, ImmunologicSex FactorsSmokingSocioeconomic FactorsTumor Suppressor ProteinsUnited StatesConceptsImmune functionAssessment of autoantibodiesUS case-control studyPopulation-based studyTumor-associated antigensCase-control studyEnolase 1Case-control differencesNuclear mitotic apparatus protein 1Risk factorsAutoantibody reactivityImmunoglobulin EIntracranial tumorsMeningioma riskDistinctive etiologyMeningiomasInfection statusSerum samplesProtein 1MenFurther researchMulticenterHigh levelsAutoantibodiesPrevious studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply